Criminals and illicit sellers have long exploited consumer demand for popular medicines. Today’s black market is increasingly sophisticated, using polished advertising, scientific-sounding language, and misleading health claims to make counterfeit and unapproved products appear legitimate.
The consequences can be serious. Federal authorities have charged operators of fake pharmacies with allegedly selling counterfeit prescription pills to unsuspecting consumers. The Drug Enforcement Administration has warned about counterfeit pills containing fentanyl and methamphetamine being sold to people who believed they were purchasing legitimate medicines, including the popular attention deficit hyperactivity disorder medication, Adderall. More recently, the Food and Drug Administration (FDA) has taken action against sellers illegally marketing unapproved ketamine products.
Against this backdrop, the illicit weight-loss drug market is growing fast. In July alone, U.S. Customs and Border Protection recorded more than 1,400 seizures and intercepted nearly 90,000 vials of illicit GLP-1 products.
As public interest shifts toward new treatments, black-market sellers are quick to capitalize on the next medicine generating consumer buzz. Today, retatrutide is in their sights.
Retatrutide is an investigational medicine being studied in clinical trials for obesity and other diseases. It has not been approved by the FDA, and there is currently no FDA-approved version available for consumers to purchase. FDA has specifically warned that retatrutide cannot be used in drug compounding and has not been found safe and effective for any condition.
Nevertheless, products labeled “retatrutide,” “Reta,” or “GLP-3” are being sold in vials, powders, and injectables – often accompanied by claims such as “lab tested,” “pure,” or “research use only.”
These phrases are only marketing tools – and deceptive ones at that – and offer no meaningful assurances of safety. Products claiming to contain retatrutide and sold outside authorized clinical research have not undergone FDA review to establish their safety, effectiveness, or quality. Consumers may have no reliable way to determine what a product contains, where it came from, how it was manufactured, whether it was stored properly, or whether the stated dosage is accurate.
Professional packaging, medical imagery, testimonials, or scientific-sounding terminology do not transform an illegal product into a legitimate medicine. Nor does a “research use only” label make a substance safe for people.
Consumers can reduce their risk by consulting licensed healthcare providers who understand their medical history, filling prescriptions through state-licensed pharmacies, and avoiding sellers, including med spas, that offer prescription products without appropriate medical supervision.
Promising new medicines should reach patients only after their safety, effectiveness, and quality have been established. Until then, regulators must take meaningful action to shut down these deceptive sellers – and patients should not mistake black-market availability for product legitimacy.